NuVasive 過去の業績

NasdaqGS:NUVA 収益、費用、利益 ( )USD Millions
日付	収益	収益	G+A経費	研究開発費
30 Jun 23	1,226	28	653	102
31 Mar 23	1,219	20	650	100
31 Dec 22	1,202	40	634	99
30 Sep 22	1,199	-20	636	98
30 Jun 22	1,174	-40	628	98
31 Mar 22	1,159	-37	624	94
31 Dec 21	1,139	-64	610	93
30 Sep 21	1,129	-26	594	89
30 Jun 21	1,153	2	594	86
31 Mar 21	1,062	-50	563	84
31 Dec 20	1,051	-37	547	80
30 Sep 20	1,069	-9	563	77
30 Jun 20	1,065	-4	570	75
31 Mar 20	1,153	61	596	73
31 Dec 19	1,168	65	611	72
30 Sep 19	1,146	48	593	70
30 Jun 19	1,127	52	581	67
31 Mar 19	1,116	49	574	65
31 Dec 18	1,102	12	576	62
30 Sep 18	1,085	24	568	57
30 Jun 18	1,060	41	553	55
31 Mar 18	1,038	42	546	53
31 Dec 17	1,027	82	540	50
30 Sep 17	1,027	64	547	51
30 Jun 17	1,019	35	554	50
31 Mar 17	996	53	549	50
31 Dec 16	962	37	534	48
30 Sep 16	906	42	510	44
30 Jun 16	867	51	489	40
31 Mar 16	834	31	468	37
31 Dec 15	811	66	457	36
30 Sep 15	800	62	454	37
30 Jun 15	790	47	457	37
31 Mar 15	777	33	460	38
31 Dec 14	762	-17	457	37
30 Sep 14	749	-18	457	36
30 Jun 14	728	-9	446	34
31 Mar 14	703	-11	433	32
31 Dec 13	685	8	420	32
30 Sep 13	660	-1	403	33
30 Jun 13	639	-6	389	33
31 Mar 13	628	3	377	35
31 Dec 12	620	3	372	35
30 Sep 12	605	-4	368	34

質の高い収益: NUVAには$16.9M } という大きな一回限りの損失があり、過去 12 か月の財務実績が30th June, 2023に影響を及ぼしています。

利益率の向上: NUVA過去に利益を上げました。

フリー・キャッシュフローと収益の比較

過去の収益成長分析

収益動向: NUVAの収益は過去 5 年間で年間33%減少しました。

成長の加速: NUVAは昨年収益を上げたため、収益成長率を 5 年間の平均と比較することは困難です。

収益対業界: NUVA昨年収益を上げたため、昨年の収益成長をMedical Equipment業界 ( 11.7% ) と比較することは困難です。

株主資本利益率

高いROE: NUVAの自己資本利益率 ( 3.2% ) は低いとみなされます。

NuVasive 過去の業績

過去 基準チェック /16

主要情報

最近の業績更新

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

NuVasive, Inc. to Report Q2, 2023 Results on Aug 02, 2023

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

NuVasive, Inc. to Report Q1, 2023 Results on May 10, 2023

Full year 2022 earnings: EPS exceeds analyst expectations

NuVasive, Inc. to Report Q4, 2022 Results on Feb 22, 2023

Recent updates

NuVasive Files Form 15

NuVasive, Inc.(NasdaqGS:NUVA) dropped from NASDAQ Composite Index

Globus Medical, Inc. (NYSE:GMED) completed the acquisition of NuVasive, Inc. (NasdaqGS:NUVA) from BlackRock, Inc. (NYSE:BLK), The Vanguard Group, Inc., Thrivent Financial for Lutherans and others.

Globus Medical, Inc. (NYSE:GMED) completed the acquisition of NuVasive, Inc. (NasdaqGS:NUVA) from BlackRock, Inc. (NYSE:BLK), The Vanguard Group, Inc., Thrivent Financial for Lutherans and others.

Consensus EPS estimates fall by 19%

New minor risk - Earnings quality

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

NuVasive, Inc. Provides Sales Guidance for the Full Year 2023

NuVasive, Inc. to Report Q2, 2023 Results on Aug 02, 2023

NuVasive, Inc. Announces Resignation of Marc Rosenbaum as Vice President, Corporate Controller and Chief Accounting Officer

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

NuVasive, Inc. Provides Sales Guidance for the Year 2023

NuVasive, Inc., Annual General Meeting, Jun 09, 2023

NuVasive, Inc. to Report Q1, 2023 Results on May 10, 2023

Is NuVasive (NASDAQ:NUVA) Using Too Much Debt?

CEO & Director exercised options and sold US$491k worth of stock

Full year 2022 earnings: EPS exceeds analyst expectations

Globus Medical, Inc. (NYSE:GMED) entered into a definitive agreement to acquire NuVasive, Inc. (NasdaqGS:NUVA) for $3.1 billion.

NuVasive, Inc. to Report Q4, 2022 Results on Feb 22, 2023

What Does NuVasive, Inc.'s (NASDAQ:NUVA) Share Price Indicate?

NuVasive, Inc.'s (NASDAQ:NUVA) Intrinsic Value Is Potentially 48% Above Its Share Price

Capital Allocation Trends At NuVasive (NASDAQ:NUVA) Aren't Ideal

Price target decreased to US$49.25

These 4 Measures Indicate That NuVasive (NASDAQ:NUVA) Is Using Debt Reasonably Well

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

NuVasive, Inc. Revises Earnings Guidance for the Year 2022

NuVasive, Inc. Launches Tube System and Excavation Micro for Posterior Spine Surgery

NuVasive, Inc. to Report Q3, 2022 Results on Nov 09, 2022

Price target decreased to US$56.00

Nuvasive Launches Reline Cervical for Posterior Cervical Fusion as Part of the C360 Portfolio

Calculating The Intrinsic Value Of NuVasive, Inc. (NASDAQ:NUVA)

Capital Allocation Trends At NuVasive (NASDAQ:NUVA) Aren't Ideal

NuVasive Likely Undervalued, But It's Hard To Find Catalysts

Does NuVasive (NASDAQ:NUVA) Have A Healthy Balance Sheet?

NuVasive, Inc. Announces Departure of Massimo Calafiore as Executive Vice President and Chief Commercial Officer, Effective August 31, 2022

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

NuVasive, Inc. Revises Earnings Guidance for the Full Year of 2022

NuVasive Non-GAAP EPS of $0.47 misses by $0.09, revenue of $310.5M beats by $4.12M

NuVasive, Inc. to Report Q2, 2022 Results on Aug 03, 2022

NuVasive: Industry Tailwinds More Than Fairly Priced

Calculating The Intrinsic Value Of NuVasive, Inc. (NASDAQ:NUVA)

NuVasive, Inc. Announces Management Changes

Investors Could Be Concerned With NuVasive's (NASDAQ:NUVA) Returns On Capital

Now 21% undervalued after recent price drop

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

NuVasive, Inc. Revises Earnings Guidance for the Full Year of 2022

NuVasive, Inc. to Report Q1, 2022 Results on May 04, 2022

NuVasive (NASDAQ:NUVA) Has A Pretty Healthy Balance Sheet

NuVasive, Inc., Annual General Meeting, May 11, 2022

At US$56.32, Is NuVasive, Inc. (NASDAQ:NUVA) Worth Looking At Closely?

NuVasive's Turnaround Story Needs A Boost From Better Results

Full year 2021 earnings: EPS exceeds analyst expectations

NuVasive, Inc. Provides Earnings Guidance for the Full Year 2022

NuVasive, Inc. to Report Q4, 2021 Results on Feb 23, 2022

NuVasive, Inc. Appoints Andrew C. Morton as Senior Vice President and Chief Human Resources Officer, Effective February 7, 2022

Nuvasive Receives FDA Clearance for Expanded Indications of Use for Attrax Putty with Thoracolumbar Interbody Portfolio

Investors Could Be Concerned With NuVasive's (NASDAQ:NUVA) Returns On Capital

Price target decreased to US$66.19

Should You Think About Buying NuVasive, Inc. (NASDAQ:NUVA) Now?

CEO & Director exercised options and sold US$708k worth of stock

NuVasive (NASDAQ:NUVA) Has A Pretty Healthy Balance Sheet

Third quarter 2021 earnings released: US$0.42 loss per share (vs US$0.12 profit in 3Q 2020)

NuVasive, Inc. (NASDAQ:NUVA) Shares Could Be 32% Below Their Intrinsic Value Estimate

Be Wary Of NuVasive (NASDAQ:NUVA) And Its Returns On Capital

Senior VP & Chief Human Resources Officer Lucas Vitale has left the company

NuVasive, Inc. Simplify Cervical Disc Data Publishes in International Journal of Spine Surgery

Key Executive exercised options and sold US$77k worth of stock

High number of new directors

At US$59.79, Is It Time To Put NuVasive, Inc. (NASDAQ:NUVA) On Your Watch List?

過去基準チェック /16